Patent search ap:("TAKEDA PHARMACEUTICAL COMPANY LIMITED") AND inv:"Yasutomi ASANO" Page 1

1.

发明申请
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20190263832A1

公开(公告)日：2019-08-29

申请号：US16256773

申请日：2019-01-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

2.

发明申请
HETEROCYCLIC COMPOUND 审中-公开

公开(公告)号：US20180170874A1

公开(公告)日：2018-06-21

申请号：US15565891

申请日：2016-04-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasutomi ASANO , Takuto KOJIMA , Osamu KURASAWA , Tzu-Tshin WONG , Yasuhiro HIRATA , Naoki IWAMURA , Bunnai SAITO , Yuta TANAKA , Ryosuke ARAI , Shinichi IMAMURA , Kazuko YONEMORI , Yasufumi MIYAMOTO , Shuji KITAMURA , Osamu SANO

IPC: C07D211/58 , C07D471/04 , C07D498/04 , C07D513/04 , C07D519/00 , C07D215/42 , C07D401/12 , C07D417/12 , C07D405/06 , C07D413/06 , C07D401/06 , C07D417/06 , C07D401/14 , C07D417/14 , C07D413/14 , C07B59/00 , A61P35/00 , A61P3/00

CPC classification number: C07D211/58 , A61K31/437 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4468 , A61K31/451 , A61K31/452 , A61K31/4709 , A61K31/498 , A61K31/506 , A61K31/517 , A61K31/5355 , A61K31/661 , A61K33/22 , A61P3/00 , A61P35/00 , C07B59/002 , C07B2200/05 , C07D215/42 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/06 , C07D409/12 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04 , C07D513/04 , C07D519/00 , C07F5/02 , C07F9/6509

Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

3.

发明公开
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20240360156A1

公开(公告)日：2024-10-31

申请号：US18592897

申请日：2024-03-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I):

wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

4.

发明申请
HETEROCYCLIC COMPOUND 有权

公开(公告)号：US20210380565A1

公开(公告)日：2021-12-09

申请号：US17280633

申请日：2019-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu SASAKI , Yasutomi ASANO , Kazuaki TAKAMI , Masaki SETO , Haruhi ANDO

IPC: C07D405/14 , A61P1/10 , C07D407/12 , C07D413/14 , C07D417/14 , C07D407/14

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.

5.

发明申请
HETEROCYCLIC COMPOUND 有权

公开(公告)号：US20210347786A1

公开(公告)日：2021-11-11

申请号：US17280634

申请日：2019-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu SASAKI , Yasutomi ASANO , Hironobu MAEZAKI , Ayumu SATO

IPC: C07D498/04 , A61P1/00

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

6.

发明申请
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开
Title translation: 杂环化合物及其用途

公开(公告)号：US20170022222A1

公开(公告)日：2017-01-26

申请号：US15289650

申请日：2016-10-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增强作用。本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

7.

发明申请
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20150073137A1

公开(公告)日：2015-03-12

申请号：US14540699

申请日：2014-11-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

8.

发明申请
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20200317692A1

公开(公告)日：2020-10-08

申请号：US16827316

申请日：2020-03-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

9.

发明申请
HETEROCYCLIC COMPOUND 审中-公开

公开(公告)号：US20190135799A1

公开(公告)日：2019-05-09

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro ITO , Hideyuki SUGIYAMA , Osamu KUBO , Fumiaki KIKUCHI , Takeshi YASUI , Keiko KAKEGAWA , Zenichi IKEDA , Tohru MIYAZAKI , Yasuyoshi ARIKAWA , Tomohiro OKAWA , Jinichi YONEMORI , Akinori TOITA , Takuto KOJIMA , Yasutomi ASANO , Ayumu SATO , Hironobu MAEZAKI , Shinobu SASAKI , Hironori KOKUBO , Misaki HOMMA , Minoru SASAKI , Yasuhiro IMAEDA

IPC: C07D413/14 , C07D471/04 , A61P25/28 , C07D413/04 , C07D417/14

CPC classification number: C07D413/14 , A61P25/28 , C07D413/04 , C07D417/14 , C07D471/04 , C07D487/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.